2024
Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C, Cheng S. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal Of Clinical Oncology 2024, 42: 1943-1952. PMID: 38507655, DOI: 10.1200/jco.23.01604.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProton beam therapyGU toxicityProstate cancerGI toxicityBenefits of proton beam therapyIntensity-modulated radiation therapy patientsPBT patientsLocalized prostate cancerTreatment-related toxicityComparison of GIStatistically significant differenceRadiation therapyBeam therapySEER-MedicareToxicity of protonProcedure codesComparative effectiveness studiesObservational studyPatientsSignificant differenceCancerMonthsComparing GIProstate
2020
Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysisGeographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening
Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control 2020, 27: 1073274820902267. PMID: 32003227, PMCID: PMC7003204, DOI: 10.1177/1073274820902267.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancer incidenceProstate cancer incidenceHealth care service areasMetastatic diseaseCancer incidenceNational Cancer Institute's SurveillanceEnd Results (SEER) databaseLocalized prostate cancerSEER 18 registriesProstate-specific antigenPSA screeningLocalized diseaseResults databaseProstate cancerOlder menMetastatic incidenceIncidenceDiseaseDiagnosisLate changesMenRecent increaseAssociationRegistryCancer
2019
Stereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Stereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e289. DOI: 10.1016/j.ijrobp.2019.06.1829.Peer-Reviewed Original Research
2018
Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States
Bledsoe T, Park H, Rutter C, Aneja S, Nguyen PL, Yu J. Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. American Journal Of Clinical Oncology 2018, 41: 1062-1068. PMID: 29521648, DOI: 10.1097/coc.0000000000000423.Peer-Reviewed Original ResearchTreatment modality selectionInsurance statusTreatment modalitiesProstate cancerPrivate insuranceProstate cancer treatment modalitiesMultivariable logistic regression analysisInvasive surgeryModality selectionCancer-directed treatmentD'Amico risk classificationTreatment modality choiceNational Cancer DatabaseLocalized prostate cancerPatient insurance statusExternal beam radiotherapyLogistic regression analysisHealth insurance statusStrongest predictorMen ages 18Cancer treatment modalitiesClinical factorsMultivariable analysisActive surveillanceCancer DatabaseAndrogen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer
Yang D, Krasnova A, Nead K, Choueiri T, Hu J, Hoffman K, Yu J, Spratt D, Feng F, Trinh Q, Nguyen P. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Annals Of Oncology 2018, 29: 386-391. PMID: 29267861, DOI: 10.1093/annonc/mdx744.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyDuration of androgen deprivation therapyProstate cancerIncreased riskRheumatoid arthritisDeprivation therapyAutoimmune conditionsAdverse effects of ADTStage I-III prostate cancerEffects of androgen deprivation therapyCompeting risks Cox regressionPharmacological androgen deprivation therapyRA diagnosisLocalized prostate cancerKaplan-Meier ratesRisks Cox regressionInverse probability of treatment weightingProbability of treatment weightingHistory of RACohort of elderly menDiagnosis of RARisk of rheumatoid arthritisUntreated hypogonadismImmunosuppressive propertiesAutoimmune diseases
2017
Travel distance and stereotactic body radiotherapy for localized prostate cancer
Mahal B, Chen Y, Sethi R, Padilla O, Yang D, Chavez J, Muralidhar V, Hu J, Feng F, Hoffman K, Martin N, Spratt D, Yu J, Orio P, Nguyen P. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer 2017, 124: 1141-1149. PMID: 29231964, DOI: 10.1002/cncr.31190.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyProstate stereotactic body radiotherapyNational Cancer Data BaseLocalized prostate cancerShort-term efficacyProstate cancerTreated with definitive external beam radiotherapyDefinitive external beam radiotherapyDefinitive stereotactic body radiotherapyLong-term clinical implicationsFavorable disease characteristicsExternal beam radiotherapyAssociated with increased adjusted oddsMultivariate logistic regressionAcademic treatment centerAffluent zip codesBeam radiotherapyTreatment optionsDisease characteristicsRadiotherapyAdjusted oddsTreatment decisionsWhite raceYounger ageJoinpoint regressionTrends and Clinico-Sociodemographic Determinants of Stereotactic Body Radiation Therapy Use for Localized Prostate Cancer
Mahal B, Sethi R, Chen Y, Casey D, Yang D, Muralidhar V, Mahal A, Orio P, Nguyen P, Yu J. Trends and Clinico-Sociodemographic Determinants of Stereotactic Body Radiation Therapy Use for Localized Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e254. DOI: 10.1016/j.ijrobp.2017.06.1209.Peer-Reviewed Original ResearchTrends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.
Mahal B, Chen Y, Muralidhar V, Yang D, Mahal A, Yu J, Orio P, Nguyen P. Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study. Journal Of Clinical Oncology 2017, 35: e545-e545. DOI: 10.1200/jco.2017.35.6_suppl.e545.Peer-Reviewed Original ResearchStereotactic body radiotherapyLocalized prostate cancerNational Cancer Data BaseGrade prostate cancerProstate cancerLow-risk disease featuresNational Cancer Database studyExternal beam radiotherapyLong-term efficacyMultivariate logistic regressionBeam radiotherapyRadiotherapy useTherapy optionsClinical factorsMultivariable adjustmentHazard ratioAcademic centersDisease characteristicsRadiotherapyDisease featuresProstateDatabase studyCancerPatientsHigher stage
2014
Perceptions of radiation oncologists and urologists on the type of evidence that informs and changes the clinical practice of prostate cancer.
Delpe S, Shah N, Tilburt J, Karnes R, Nguyen P, Shuch B, Gross C, Schulam P, Yu J, Ziegenfuss J, Kim S. Perceptions of radiation oncologists and urologists on the type of evidence that informs and changes the clinical practice of prostate cancer. Journal Of Clinical Oncology 2014, 32: 167-167. DOI: 10.1200/jco.2014.32.4_suppl.167.Peer-Reviewed Original ResearchLevel of evidenceProstate cancerSpecialty-specific journalsRadiation oncologistsTreatment recommendationsClinical practiceClinical guidelinesMultivariable logistic regression modelLocalized prostate cancerNew treatment paradigmProstate cancer specialistsProstate cancer treatmentLogistic regression modelsNational survey studySurvey response ratePhysician characteristicsTreatment paradigmCancer specialistsResponse rateOncologistsUrologistsCancerCancer treatmentRCTsCancer journals
2013
Interpreting cost-utility analysis of prostate cancer treatment
Yu J. Interpreting cost-utility analysis of prostate cancer treatment. Nature Reviews Urology 2013, 10: 129-131. PMID: 23399726, DOI: 10.1038/nrurol.2013.17.Peer-Reviewed Original ResearchConceptsLocalized prostate cancerProstate cancer treatmentProstate cancerCancer treatmentCost-utility analysis
2010
Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort
Schreiber D, Rineer J, Yu J, Olsheski M, Nwokedi E, Schwartz D, Choi K, Rotman M. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 2010, 116: 5757-5766. PMID: 20737571, DOI: 10.1002/cncr.25561.Peer-Reviewed Original ResearchConceptsProstate-specific antigenClinically localized prostate cancerPositive surgical marginsLocalized prostate cancerAdjuvant radiationRadical prostatectomySurgical marginsProstate cancerPathologic extentRate of organ-confined diseaseProstate-specific antigen levelRisk of extraprostatic extensionPatterns of care studyOrgan-confined diseaseNegative surgical marginsEnd Results databaseLogistic regression analysisPopulation-based studyExtraprostatic diseaseExtraprostatic extensionGleason 7Gleason 8Postoperative radiationProstatic adenocarcinomaResults databaseAdjuvant radiotherapy after radical prostatectomy: Evidence and analysis
Raldow A, Hamstra D, Kim S, Yu J. Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. Cancer Treatment Reviews 2010, 37: 89-96. PMID: 20667660, DOI: 10.1016/j.ctrv.2010.07.001.Peer-Reviewed Original ResearchConceptsTarget volumeIncreased risk of cancer recurrencePositive surgical marginsSeminal vesicle invasionTreatment target volumeLocalized prostate cancerRisk of cancer recurrenceSigns of recurrenceTreatment of patientsTechnical aspects of treatmentDecrease side effectsRandomized clinical trialsUndetectable PSAAdjuvant radiotherapyAdjuvant settingDose escalationExtracapsular extensionRadical prostatectomySurgical marginsRadiation therapyProstate cancerPathological examinationClinical outcomesCure rateCancer recurrence